Summit Therapeutics Inc. (SMMT)

7.80 -0.07 (-0.89%) 收市：04:00PM EDT

Summit Therapeutics Inc.

601 Brickell Key Drive
Suite 1000
Miami, FL 33131
United States
650 460 8308
https://www.summittxinc.com

版塊: Healthcare
行業: Biotechnology
全職員工: 105

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Robert W. Duggan	Co-CEO & Executive Chairman	無	無	1945
Dr. Mahkam Zanganeh D.D.S., M.B.A.	Co-CEO, President & Director	657.81k	無	1970
Mr. Manmeet Singh Soni	COO, CFO & Director	591.5k	無	1978
Prof. Dame Kay Davies DBE, FRS CBE	Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor	無	無	1951
Mr. Bhaskar Anand	Chief Accounting Officer & Head of Finance	無	無	1978
Ms. Abby Guzman Murphy	Head of Human Resources	無	無	無
Ms. Divya Chari	Head of Global Clinical Operations	無	無	1968
Mr. Dave Gancarz	Chief Business & Strategy Officer?	無	無	無
Dr. Betty Y. Chang Ph.D.	Head of Research, Oncology & Inflammation?	無	無	無
Dr. Fong Clow	Chief Biometrics Officer?	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

公司管治

截至 2024年6月1日 止，Summit Therapeutics Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：6；董事會：8；股東權利：5；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。